Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 33Leukemia, Lymphocytic, Chronic, B-Cell 30Lymphoma, Mantle-Cell 26Lymphoma, Follicular 17Waldenstrom Macroglobulinemia 14Lymphoma, B-Cell, Marginal Zone 14Recurrence 12Lymphoma 12Lymphoma, B-Cell 9Lymphoma, Non-Hodgkin 6Leukemia 4B-cell Malignancies 3Neoplasms 2Hematologic Neoplasms 2Myelodysplastic Syndromes 1Multiple Myeloma 1Mature B-Cell Malignancies 1Lymphoma, T-Cell 1Lymphohistiocytosis, Hemophagocytic 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Leukemia, B-Cell 1Intraocular Lymphoma 1Hematologic Diseases 1Dendritic Cell Sarcoma, Interdigitating 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 76fludarabine phosphate 41Filgrastim 38Peripheral Blood Stem Cell Transplantation 34Radiotherapy 33Cyclosporine 32Busulfan 31Etoposide 30Mycophenolic Acid 29Antilymphocyte Serum 28Whole-Body Irradiation 25Methotrexate 25Rituximab 22Melphalan 21Methylprednisolone 20Vincristine 17Tacrolimus 16Doxorubicin 16Cytarabine 16Cord Blood Stem Cell Transplantation 16Prednisone 15Thiotepa 10Granulocyte Colony-Stimulating Factor 9Carboplatin 8Leucovorin 7fludarabine 6aldesleukin 6Ifosfamide 6sargramostim 5Sirolimus 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Dendritic Cell Sarcoma, Interdigitating × zanubrutinib × Clear all
NCT06846463 2026-01-23

Zanubrutinib in Patients With DLBCL and MYD88 or NOTCH1 Mutation or CD5+

Virginia Commonwealth University

Phase 2 Recruiting
21 enrolled
LymphoidSarcoma

Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡